The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breastcancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Some results have been hidden because they may be inaccessible to you